Antifibrotic Drugs Market
完整報告名稱與涵蓋範圍
Antifibrotic Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Pirfenidone and Nintedanib, Novel Antifibrotic Agents (PDE4B, LPA1, Integrin and Other Targets), Biologics and Peptide Antifibrotics), By Indication (Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, Liver Fibrosis and MASH, Systemic Sclerosis and Other Fibrotic Diseases), By Route of Administration (Oral, Inhaled, Injectable), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The antifibrotic drugs market covers approved and pipeline therapies that slow or reverse fibrosis in the lung, liver, skin and other organs, including the established oral agents for idiopathic pulmonary fibrosis, newly approved mechanisms such as PDE4B inhibition, and candidates directed at LPA1, integrins, galectins and other fibrosis pathways. Supportive care, oxygen therapy and transplantation are excluded, as are metabolic drugs for liver disease unless their labelled indication references fibrosis improvement.
The category is at an inflection point after nearly a decade in which two oral agents dominated pulmonary fibrosis treatment with modest efficacy and tolerability limits. Phase 3 successes for new mechanisms, the first approvals for liver fibrosis in metabolic dysfunction-associated steatohepatitis and an inhaled reformulation strategy that reduces systemic side effects are expanding the treatable population and enabling combination regimens. Diagnostic advances, including quantitative CT and blood-based fibrosis markers, support earlier treatment, while high failure rates in fibrosis trials keep development risk elevated.
North America and Europe account for most revenue given diagnosis rates and reimbursement, with Japan a significant market and China expanding access to novel agents. Competition combines respiratory and liver franchise holders with specialist biotechnology companies advancing first-in-class mechanisms.
The InsightAce study delivers revenue forecasts in US$ across all drug class, indication, route of administration and distribution channel and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antifibrotic Drugs Market Snapshot
Chapter 4. Global Antifibrotic Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. Pirfenidone and Nintedanib
5.2.2. Novel Antifibrotic Agents (PDE4B, LPA1, Integrin and Other Targets)
5.2.3. Biologics and Peptide Antifibrotics
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
6.2.2. Liver Fibrosis and MASH
6.2.3. Systemic Sclerosis and Other Fibrotic Diseases
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Oral
7.2.2. Inhaled
7.2.3. Injectable
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Specialty and Retail Pharmacies
Chapter 9. Antifibrotic Drugs Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Boehringer Ingelheim International GmbH
11.2. Roche Holding AG
11.3. Bristol Myers Squibb
11.4. Pliant Therapeutics, Inc.
11.5. United Therapeutics Corporation
11.6. Avalyn Pharma Inc.
11.7. Madrigal Pharmaceuticals, Inc.
11.8. Novartis AG
11.9. FibroGen, Inc.
11.10. Vicore Pharma Holding AB
11.11. Endeavor BioMedicines, Inc.
11.12. Insilico Medicine
11.13. Galecto, Inc.
11.14. Sanofi
11.15. Zydus Lifesciences Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Antifibrotic Drugs Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Global Antifibrotic Drugs Market Snapshot, 2026 & 2035
Table 2. Global Antifibrotic Drugs Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Antifibrotic Drugs Market Share by Indication, 2026 & 2035
Table 3. Global Antifibrotic Drugs Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Antifibrotic Pipeline by Mechanism, Organ System and Phase, 2026
Table 4. Global Antifibrotic Drugs Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Treatment Paradigm Shift in Pulmonary Fibrosis with New Mechanisms and Combinations
Table 5. North America Antifibrotic Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Antifibrotic Drugs Growth Opportunity Analysis
Table 6. Europe Antifibrotic Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Diagnosed and Treated Population Growth in Pulmonary and Liver Fibrosis, 2026-2035
Table 7. Asia Pacific Antifibrotic Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Antifibrotic Drugs Market Participants
Table 8. Latin America and Middle East & Africa Antifibrotic Drugs Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們